VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT)
(OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces its research arm, Cannevert Therapeutics Ltd.
(“CTL”) has signed a Material Transfer Agreement with the Institute for Medical Cannabis (“IMC”)
Corporation of Puerto Rico. IMC will provide Cannevert with specific cannabis strains for upcoming human studies in the US
territory.
IMC is the first licensed medical cannabis company under the State Department Medical Cannabis Health Code to
supply a variety of the high quality medical cannabis products for the medical community. It has a state of the art facility
in Ponce that provides cultivation, extraction, formulation, multiple forms of production, and research using the best, award
winning strains, technology and processes in the industry.
IMC operates in a 44,000-square-foot building with 15,000 square feet of indoor cannabis under lights with an
additional 1,800 square feet of ISO Class 7 cleanroom class manufacturing space. For more information about IMC, please visit their
website at http://imc-pr.com.
Veritas’ CEO, Dr. Lui Franciosi, stated “We are pleased that Cannevert has identified a reputable producer that
is focused on providing certified quality products, educating the medical community on the potential benefits of cannabis, and
conducting clinical research on its products. They will enable us to get medical grade strains of interest into the clinic and
scientifically evaluated against different kinds of pain.”
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through its 80% owned
Cannevert Therapeutics Ltd. ("CTL"), is advancing the science behind medical cannabis. It is the Company aim, through its
investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving
the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research
and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management
team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's commercial mission is to patent
protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting
multi-billion dollar global markets.
Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the
Canadian Securities Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the
Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors
"Dr. Lui Franciosi"
Dr. Lui Franciosi
President and Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website
at www.thecse.com.
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press
release.
